妊娠期接种COVID-19加强疫苗可增强母体结合抗体和中和抗体反应及向新生儿的经胎盘抗体转移
该前瞻性多中心队列研究纳入2021年7月至2022年1月在9个学术中心妊娠期接种mRNA COVID-19疫苗的240名参与者,比较基础两剂系列与加强剂接种后的结合抗体和中和抗体滴度及经胎盘转移效率。加强接种后母体分娩时血清和脐血中针对包括Omicron BA.1在内的结合抗体和中和抗体滴度显著高于基础两剂系列。研究结论支持妊娠期使用COVID-19疫苗加强剂。
要点
- 加强接种后母体分娩时血清和脐血结合及中和抗体滴度显著高于基础两剂系列。
- 分娩时活病毒中和抗体对Omicron BA.1的阳性率:辉瑞基础系列9%,莫德纳基础系列22%,mRNA加强接种者73%。
- 所有接种方案的经胎盘抗体转移效率均良好,IgG中位转移比范围为1.55-1.77。
核心结论
- 妊娠期接种COVID-19 mRNA疫苗可在母体引发稳健免疫应答并向新生儿有效经胎盘转移抗体。
- 妊娠期加强接种显著提高母体和脐血结合抗体及中和抗体水平,包括针对Omicron BA.1的抗体。
- 研究结果支持妊娠期使用COVID-19疫苗加强剂。
研究设计与样本
- 前瞻性多中心队列研究,2021年7月至2022年1月在9个学术中心纳入妊娠期接种mRNA COVID-19疫苗的参与者。
- 共240名参与者接种辉瑞或莫德纳mRNA疫苗,其中基础两剂系列167人,加强剂73人。
- 检测接种前后及分娩时母体和婴儿的SARS-CoV-2结合抗体及活病毒和假病毒中和抗体滴度。
- 在调整末次接种后天数后,比较基础与加强接种者分娩时母体血清和脐血中对祖先株和Omicron BA.1株的免疫应答。
主要发现
- 加强接种后分娩时母体血清和脐血中结合抗体和中和抗体滴度显著高于基础两剂系列,包括针对Omicron BA.1的抗体,范围高0.44-0.88 log10,所有比较P<0.0001。
- 分娩时活病毒中和抗体对Omicron BA.1的阳性率:辉瑞基础系列9%(GMT ID50 12.7),莫德纳基础系列22%(GMT ID50 14.7),mRNA加强接种者73%(GMT ID50 60.2),P<0.0001。
- 对Omicron BA.1的中和抗体滴度显著低于对D614G株的滴度。
- 所有接种方案的经胎盘抗体转移效率均良好,中位转移比范围:IgG 1.55-1.77,活病毒中和抗体1.00-1.78,假病毒中和抗体1.79-2.36。
临床怎么用
- 研究结果支持妊娠期使用COVID-19疫苗加强剂。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The immune response to COVID-19 booster vaccinations during pregnancy for mothers and their newborns and the functional response of vaccine-induced antibodies against Omicron variants are not well characterized. We conducted a prospective, multicenter cohort study of participants vaccinated during pregnancy with primary or booster mRNA COVID-19 vaccines from July 2021 to January 2022 at 9 academic sites. We determined SARS-CoV-2 binding and live virus and pseudovirus neutralizing antibody (nAb) titers pre- and post-vaccination, and at delivery for both maternal and infant participants. Immune responses to ancestral and Omicron BA.1 SARS-CoV-2 strains were compared between primary and booster vaccine recipients in maternal sera at delivery and in cord blood, after adjusting for days since last vaccination. A total of 240 participants received either Pfizer or Moderna mRNA vaccine during pregnancy (primary 2-dose series: 167; booster dose: 73). Booster vaccination resulted in significantly higher binding and nAb titers, including to the Omicron BA.1 variant, in maternal serum at delivery and in cord blood compared to a primary 2-dose series (range 0.44-0.88 log10 higher, p < 0.0001 for all comparisons). Live virus nAb to Omicron BA.1 were present at delivery in 9 % (GMT ID50 12.7) of Pfizer and 22 % (GMT ID50 14.7) of Moderna primary series recipients, and in 73 % (GMT ID50 60.2) of mRNA boosted participants (p < 0.0001), although titers were significantly lower than to the D614G strain. Transplacental antibody transfer was efficient for all regimens with median transfer ratio range: 1.55-1.77 for IgG, 1.00-1.78 for live virus nAb and 1.79-2.36 for pseudovirus nAb. COVID-19 mRNA vaccination during pregnancy elicited robust immune responses in mothers and efficient transplacental antibody transfer to the newborn. A booster dose during pregnancy significantly increased maternal and cord blood binding and neutralizing antibody levels, including against Omicron BA.1. Findings support the use of a booster dose of COVID-19 vaccine during pregnancy.
引用
- Munoz FM, Posavad CM, Richardson BA, et al. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn. Vaccine. 2023. PMID: 37451878. doi:10.1016/j.vaccine.2023.06.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。